In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adocia SAS

www.adocia.com

Latest From Adocia SAS

Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?

A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.

Strategy Clinical Trials

ADA Meeting's Around The Corner: Five Things To Watch For

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Clinical Trials Research & Development

Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology

Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.
Deals Commercial

Pipeline Watch: Phase III Studies of CSL112 And RT-100 Imminent

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Adocia SAS
  • Senior Management
  • Gerard Soula, PhD, Pres. & CEO
    Valerie Danaguezian, CFO
    Olivier Soula, PhD, Dir, R&D
    Remi Soula, PhD, Dir., Bus. Dev. & IP
  • Contact Info
  • Adocia SAS
    Phone: (33) 4 726 10610
    115 Ave. Lacassagne
    Lyon, 69003
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register